Approximately one-third of patients discharged following hospitalization for acute stroke are referred to community-based rehabilitation. Among patients discharged home after hospitalization for mild ...

Discontinuation of DMTs was associated with a higher risk for disease activity among patients with MS. Patients with multiple sclerosis (MS) who discontinued disease-modifying therapies (DMTs ...

Compared with patients with CIDP who received placebo, those who received efgartigimod PH20 showed a decreased risk for clinical deterioration. Patients with chronic inflammatory demyelinating ...

Treatment optimization for patients with migraine was considered “poor” with more than 11% discontinuing triptans. Treatment optimization is reported to be “poor” among patients with ...

Compared with placebo, vutrisiran therapy led to improved neurologic function and quality of life in patients with hATTR amyloidosis with polyneuropathy. Treatment with vutrisiran improved ...

Treatment with fremanezumab over a 6-month period was effective and well-tolerated in patients with both migraine and obesity. Fremanezumab is found to be safe and effective in patients with ...

Compared with placebo, dextromethorphan-bupropion increased time to relapse for agitation symptoms in patients with Alzheimer disease. Oral glutamate receptor antagonist dextromethorphan-bupropion ...

Clinically meaningful milestones measuring ambulatory decline in patients with Duchenne muscular dystrophy are delayed by ataluren therapy. Ataluren delays clinically meaningful milestones of ...

The incidence of Parkinson disease is reduced in patients with autoimmune diseases who receive anti-inflammatory therapy, particularly anti-tumor necrosis factor and anti-interleukin-17 treatment.

Approximately 30% and over 50% of older adults with insomnia disorder and objective short sleep who were treated with lemborexant for 1 month achieved remission and responded to treatment ...

Black patients, men, older adults, and those living in rural locations were less likely to receive thrombolysis after acute ischemic stroke. Gender, age, and race and ethnicity are predictors for ...

Among adults with AChRAb+ generalized myasthenia gravis, intravenous ravulizumab administered every 8 weeks was associated with sustained efficacy and safety. Ravulizumab is associated with ...